11 – 20 of 23
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway
(
- Contribution to journal › Article
- 2016
-
Mark
Reference measurement procedure for CSF amyloid beta (Aβ)1–42 and the CSF Aβ1–42/Aβ1–40 ratio – a cross-validation study against amyloid PET
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression
(
- Contribution to journal › Article
- 2015
-
Mark
Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease.
(
- Contribution to journal › Article
- 2014
-
Mark
Assessment of Peptide Chemical Modifications on the Development of an Accurate and Precise Multiplex Selected Reaction Monitoring Assay for Apolipoprotein E Isoforms
(
- Contribution to journal › Article
- 2013
-
Mark
A beta 1-15/16 as a Potential Diagnostic Marker in Neurodegenerative Diseases
(
- Contribution to journal › Article
-
Mark
A Selected Reaction Monitoring (SRM)-Based Method for Absolute Quantification of A beta(38), A beta(40), and A beta(42) in Cerebrospinal Fluid of Alzheimer's Disease Patients and Healthy Controls
(
- Contribution to journal › Article